Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.

(Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is ...

Commercial terms include an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments SEATTLE, Jan. 7, 2025 /PRNewswire ...

Collaboration aims to identify and validate novel targets with strong genetic evidence and clear therapeutic hypotheses The partnership between Novo Nordisk and Variant Bio is aimed at identifying ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.

Under the terms of the agreement, Novo Nordisk will pay Variant Bio an upfront payment and additional near-term R&D funding totaling up to $50 million, plus potential option and milestone payments ...

Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populations.